TY - JOUR
T1 - Wiskott-Aldrich syndrome protein interacts and inhibits diacylglycerol kinase alpha promoting IL-2 induction
AU - Velnati, Suresh
AU - Centonze, Sara
AU - Rossino, Giulia
AU - Purghè, Beatrice
AU - ANTONA, ANNAMARIA
AU - Racca, Luisa
AU - Mula, Sabrina
AU - Ruffo, Elisa
AU - MALACARNE, VALERIA
AU - MALERBA, Mario
AU - MANFREDI, MARCELLO
AU - Graziani, Andrea
AU - BALDANZI, GIANLUCA
N1 - Publisher Copyright:
Copyright © 2023 Velnati, Centonze, Rossino, Purghè, Antona, Racca, Mula, Ruffo, Malacarne, Malerba, Manfredi, Graziani and Baldanzi.
PY - 2023
Y1 - 2023
N2 - Background: Phosphorylation of diacylglycerol by diacylglycerol-kinases represents a major inhibitory event constraining T cell activation upon antigen engagement. Efficient TCR signalling requires the inhibition of the alpha isoform of diacylglycerol kinase, DGKα, by an unidentified signalling pathway triggered by the protein adaptor SAP. We previously demonstrated that, in SAP absence, excessive DGKα activity makes the T cells resistant to restimulation-induced cell death (RICD), an apoptotic program counteracting excessive T cell clonal expansion. Results: Herein, we report that the Wiskott-Aldrich syndrome protein (WASp) inhibits DGKα through a specific interaction of the DGKα recoverin homology domain with the WH1 domain of WASp. Indeed, WASp is necessary and sufficient for DGKα inhibition, and this WASp function is independent of ARP2/3 activity. The adaptor protein NCK-1 and the small G protein CDC42 connect WASp-mediated DGKα inhibition to SAP and the TCR signalosome. In primary human T cells, this new signalling pathway is necessary for a full response in terms of IL-2 production, while minimally affecting TCR signalling and restimulation-induced cell death. Conversely, in T cells made resistant to RICD by SAP silencing, the enhanced DAG signalling due to DGKα inhibition is sufficient to restore apoptosis sensitivity. Conclusion: We discover a novel signalling pathway where, upon strong TCR activation, the complex between WASp and DGKα blocks DGKα activity, allowing a full cytokine response.
AB - Background: Phosphorylation of diacylglycerol by diacylglycerol-kinases represents a major inhibitory event constraining T cell activation upon antigen engagement. Efficient TCR signalling requires the inhibition of the alpha isoform of diacylglycerol kinase, DGKα, by an unidentified signalling pathway triggered by the protein adaptor SAP. We previously demonstrated that, in SAP absence, excessive DGKα activity makes the T cells resistant to restimulation-induced cell death (RICD), an apoptotic program counteracting excessive T cell clonal expansion. Results: Herein, we report that the Wiskott-Aldrich syndrome protein (WASp) inhibits DGKα through a specific interaction of the DGKα recoverin homology domain with the WH1 domain of WASp. Indeed, WASp is necessary and sufficient for DGKα inhibition, and this WASp function is independent of ARP2/3 activity. The adaptor protein NCK-1 and the small G protein CDC42 connect WASp-mediated DGKα inhibition to SAP and the TCR signalosome. In primary human T cells, this new signalling pathway is necessary for a full response in terms of IL-2 production, while minimally affecting TCR signalling and restimulation-induced cell death. Conversely, in T cells made resistant to RICD by SAP silencing, the enhanced DAG signalling due to DGKα inhibition is sufficient to restore apoptosis sensitivity. Conclusion: We discover a novel signalling pathway where, upon strong TCR activation, the complex between WASp and DGKα blocks DGKα activity, allowing a full cytokine response.
KW - DGK diacylglycerol kinase
KW - SLAM-associated protein (SAP)
KW - T cell receptor signalling
KW - WAS (Wiskott-Aldrich syndrome)
KW - X-linked lymphoproliferative disease (XLP)
KW - restimulation-induced cell death
KW - DGK diacylglycerol kinase
KW - SLAM-associated protein (SAP)
KW - T cell receptor signalling
KW - WAS (Wiskott-Aldrich syndrome)
KW - X-linked lymphoproliferative disease (XLP)
KW - restimulation-induced cell death
UR - https://iris.uniupo.it/handle/11579/153380
U2 - 10.3389/fimmu.2023.1043603
DO - 10.3389/fimmu.2023.1043603
M3 - Article
SN - 1664-3224
VL - 14
SP - 1043603
JO - Frontiers in Immunology
JF - Frontiers in Immunology
ER -